446 related articles for article (PubMed ID: 19561323)
1. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
5. New treatments in multiple myeloma: beyond optimal treatment.
Harousseau JL
Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
[No Abstract] [Full Text] [Related]
6. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and therapy of multiple myeloma.
Palumbo A; Cerrato C
Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
[TBL] [Abstract][Full Text] [Related]
8. [A cure for multiple myeloma?].
Harousseau JL
Presse Med; 2006 Sep; 35(9 Pt 2):1288-90. PubMed ID: 16969322
[No Abstract] [Full Text] [Related]
9. Maintenance treatment in multiple myeloma.
Harousseau JL
Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
[No Abstract] [Full Text] [Related]
10. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: novel approaches for relapsed disease.
Lonial S
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
[TBL] [Abstract][Full Text] [Related]
12. [Recent progress in diagnosis of and therapy for multiple myeloma].
Okamoto S
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1922-31. PubMed ID: 17037337
[No Abstract] [Full Text] [Related]
13. Treatment of newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
[TBL] [Abstract][Full Text] [Related]
14. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies in the treatment of multiple myeloma.
Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
[TBL] [Abstract][Full Text] [Related]
16. Current multiple myeloma treatment strategies with novel agents: a European perspective.
Ludwig H; Beksac M; Bladé J; Boccadoro M; Cavenagh J; Cavo M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau JL; Hess U; Ketterer N; Kropff M; Mendeleeva L; Morgan G; Palumbo A; Plesner T; San Miguel J; Shpilberg O; Sondergeld P; Sonneveld P; Zweegman S
Oncologist; 2010; 15(1):6-25. PubMed ID: 20086168
[TBL] [Abstract][Full Text] [Related]
17. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
[TBL] [Abstract][Full Text] [Related]
18. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
McCarthy PL
J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and management guideline for multiple myeloma].
Murakami H; Handa H; Saitoh T
Nihon Rinsho; 2007 Dec; 65(12):2167-76. PubMed ID: 18069257
[TBL] [Abstract][Full Text] [Related]
20. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Benson DM; Panzner K; Hamadani M; Hofmeister CC; Bakan CE; Smith MK; Elder P; Krugh D; O'Donnell L; Devine SM
Leuk Lymphoma; 2010 Feb; 51(2):243-51. PubMed ID: 20038230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
